z-logo
open-access-imgOpen Access
Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.
Author(s) -
Thomas D.Y. Chung,
Fred H. Drake,
K. B. Tan,
Steven R. Per,
Stanley T. Crooke,
Christopher K. Mirabelli
Publication year - 1989
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.86.23.9431
Subject(s) - complementary dna , biology , cdna library , microbiology and biotechnology , isozyme , nucleic acid sequence , dna , oligonucleotide , topoisomerase , genomic dna , gene , genetics , biochemistry , enzyme
Several DNA topoisomerase II (Topo II; EC 5.99.1.3) partial cDNA clones obtained from a human Raji-HN2 cDNA library were sequenced and two classes of nucleotide sequences were found. One member of the first class, SP1, was identical to an internal fragment of human HeLa cell Topo II cDNA described earlier. A member of the second class, SP11, shared extensive nucleotide (75%) and predicted peptide (92%) sequence similarities with the first two-thirds of HeLa Topo II. Each class of cDNAs hybridized to unique, nonoverlapping restriction enzyme fragments of genomic DNA from several human cell lines. Synthetic 24-mer oligonucleotide probes specific for each cDNA class hybridized to 6.5-kilobase mRNAs; furthermore, hybridization of probe specific for one class was not blocked by probe specific for the other. Antibodies raised against a synthetic SP1-encoded dodecapeptide specifically recognized the 170-kDa form of Topo II, while antibodies raised against the corresponding SP11-encoded dodecapeptide, or a second unique SP11-encoded tridecapeptide, selectively recognized the 180-kDa form of Topo II. These data provide genetic and immunochemical evidence for two Topo II isozymes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here